Rapport Therapeutics, Inc.
RAPP
$38.08
$0.842.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 67.16% | -- | -- | -- | -- |
| Gross Profit | 35.03% | -- | -- | -- | -- |
| SG&A Expenses | 52.59% | 30.51% | 26.41% | 33.36% | 64.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.11% | 63.72% | 38.57% | 41.81% | 58.58% |
| Operating Income | 10.67% | -63.72% | -38.57% | -41.81% | -58.58% |
| Income Before Tax | 17.48% | -68.98% | -53.53% | -47.52% | -6.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.48% | -68.98% | -53.53% | -47.52% | -6.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.48% | -68.98% | -53.53% | -47.52% | -6.15% |
| EBIT | 10.67% | -63.72% | -38.57% | -41.81% | -58.58% |
| EBITDA | 10.71% | -64.41% | -38.79% | -42.02% | -58.56% |
| EPS Basic | 38.38% | -26.15% | -41.09% | 55.61% | 93.84% |
| Normalized Basic EPS | 38.39% | -26.14% | -41.05% | 55.60% | 90.86% |
| EPS Diluted | 38.38% | -26.15% | -41.09% | 55.61% | 93.84% |
| Normalized Diluted EPS | 38.39% | -26.14% | -41.05% | 55.60% | 90.86% |
| Average Basic Shares Outstanding | 33.94% | 33.96% | 8.82% | 232.30% | 1,622.93% |
| Average Diluted Shares Outstanding | 33.94% | 33.96% | 8.82% | 232.30% | 1,622.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |